FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1275 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... January 12, 2026 Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ January 8, 2025 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS Mom Wants Disney To Ban Childless Adults From Their Theme Parks EMA Recommends Granting a Marketing Authorisation for Azacitidine What Are Drug Shortages and How Can They Impact Care for... Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast
